Neutralization of a Clade B Primary Isolate by Sera From Human Immunodeficiency Virus-Uninfected Recipients of Candidate AIDS Vaccines

J Infect Dis. 1997 Apr;175(4):764-74. doi: 10.1086/513969.


The inability of antibodies induced by experimental human immunodeficiency virus type 1 (HIV-1) vaccines to neutralize HIV-1 primary isolates may be due to a failure to elicit such antibodies, antigenic differences between the vaccine and the strains tested, insensitivity of the assays used, or to a combination of factors. New neutralization assays were used to determine the ability of candidate AIDS vaccines to generate neutralizing antibodies for clade B primary isolate BZ167, which is closely related in portions of its envelope to the immunizing strains. Sera from HIV-uninfected volunteers in vaccine trials were tested, and neutralizing activity was found in recipients of recombinant (r) gp120MN or of rgp160MN-containing canarypox boosted with rgp120SF-2. Detection of antibodies that neutralize primary isolate BZ167 correlated with neutralizing activity for homologous vaccine strains. These data demonstrate that certain candidate AIDS vaccines can elicit antibodies that neutralize a primary isolate of HIV-1.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS Vaccines / immunology*
  • Adolescent
  • Adult
  • Female
  • HIV Antibodies / blood*
  • HIV Envelope Protein gp120 / immunology
  • HIV-1 / immunology*
  • Humans
  • Male
  • Middle Aged


  • AIDS Vaccines
  • HIV Antibodies
  • HIV Envelope Protein gp120